Annovis Bio
ANVS
61 hedge funds and large institutions have $20.2M invested in Annovis Bio in 2026 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 6 reducing their positions, and 11 closing their positions.
390% more call options, than puts
Call options by funds: $2.71M | Put options by funds: $554K
200% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 6
92% more capital invested
Capital invested by funds: $10.5M → $20.2M (+$9.66M)
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
14.67% more ownership
Funds ownership: 16.65% → 31.32% (+15%)
9% more funds holding
Funds holding: 56 → 61 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
+$4.67M |
| 2 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$2.64M |
| 3 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$1.51M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$1.27M |
| 5 |
Renaissance Technologies
New York
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFG
Merit Financial Group
Alpharetta,
Georgia
|
-$181K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$143K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$139K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$135K |
| 5 |
Two Sigma Investments
New York
|
-$93.5K |
ANVS Hedge Fund Activity: Q2 2026 in Review
61 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q2 2026, worth a combined $20.2M — up 92% from $10.5M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ANVS positions and 11 closed out — a net gain of 5 holders — while 18 added to existing stakes and 6 trimmed.
The largest buyer was Empery Asset Management, opening a new position worth an estimated $4.67M. The largest seller was Merit Financial Group, exiting entirely with an estimated $181K sold.
- 61 institutional investors held Annovis Bio (ANVS) as of Q2 2026, up from 56 in Q1 2026.
- Funds reported $20.2M of Annovis Bio stock for Q2 2026, up 92% quarter-over-quarter.
- 16 funds opened new Annovis Bio positions in Q2 2026 and 11 closed out, a net change of +5 holders.
- The largest Annovis Bio buyer in Q2 2026 was Empery Asset Management, an estimated $4.67M added.
- The largest Annovis Bio seller in Q2 2026 was Merit Financial Group, an estimated $181K sold.
Based on aggregated 13F filings for Q2 2026.